TAAR1 and laryngotracheoesophageal cleft: Continuous injection of Tα1 for more than 24 months had the best therapeutic effect in studies of Tα1 as a postoperative adjuvant therapy for LC patients, but there were significant differences in the duration of Tα1 use in other studies, such as clinical trials investigating the therapeutic effect of Tα1 on CCRT-induced side effects, which were used from the beginning of receiving CCRT to 2 months after the end of CCRT.